The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).
 
Caio Max Sao Pedro Rocha Lima
Honoraria - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Xcenda; Xcenda; Xcenda; Xcenda
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Merck; Merck; Merck; Merck; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals
 
Greg Yothers
Employment - Mountainview Pediatrics (I); Mountainview Pediatrics (I); Mountainview Pediatrics (I); Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Orbus Therapeutics; Orbus Therapeutics; Orbus Therapeutics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics
 
Samuel A. Jacobs
No Relationships to Disclose
 
Hanna Kelly Sanoff
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst)
 
Deirdre Jill Cohen
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Katherine A Guthrie
No Relationships to Disclose
 
Norah Lynn Henry
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Patricia A. Ganz
Leadership - Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Intrinsic LifeSciences (I)
Stock and Other Ownership Interests - Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Silarus Therapeutics (I); Silarus Therapeutics (I); Silarus Therapeutics (I); Silarus Therapeutics (I); Teva; Teva; Teva; Teva; xenon pharma (I); xenon pharma (I); xenon pharma (I); xenon pharma (I)
Consulting or Advisory Role - Akebia Therapeutics (I); Akebia Therapeutics (I); Akebia Therapeutics (I); Akebia Therapeutics (I); Ambys Medicines (I); Ambys Medicines (I); Ambys Medicines (I); Ambys Medicines (I); bioverativ (I); bioverativ (I); bioverativ (I); bioverativ (I); Gilead Sciences (I); Gilead Sciences (I); Gilead Sciences (I); Gilead Sciences (I); GlaxoSmithKline (I); GlaxoSmithKline (I); GlaxoSmithKline (I); GlaxoSmithKline (I); Global Blood Therapeutics (I); Global Blood Therapeutics (I); Global Blood Therapeutics (I); Global Blood Therapeutics (I); InformedDNA; InformedDNA; InformedDNA; InformedDNA; ION Pharma (I); ION Pharma (I); ION Pharma (I); ION Pharma (I); Keryx (I); Keryx (I); Keryx (I); Keryx (I); La Jolla Pharma (I); La Jolla Pharma (I); La Jolla Pharma (I); La Jolla Pharma (I); Protagonist Therapeutics (I); Protagonist Therapeutics (I); Protagonist Therapeutics (I); Protagonist Therapeutics (I); Regeneron (I); Regeneron (I); Regeneron (I); Regeneron (I); Sierra Oncology (I); Sierra Oncology (I); Sierra Oncology (I); Sierra Oncology (I); Silarus Therapeutics (I); Silarus Therapeutics (I); Silarus Therapeutics (I); Silarus Therapeutics (I); Vifor Pharma (I); Vifor Pharma (I); Vifor Pharma (I); Vifor Pharma (I)
Research Funding - Keryx (I); Keryx (I); Keryx (I); Keryx (I); Sierra Oncology (I); Sierra Oncology (I); Sierra Oncology (I); Sierra Oncology (I)
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I); related to iron metabolism and the anemia of chronic disease (I); related to iron metabolism and the anemia of chronic disease (I); related to iron metabolism and the anemia of chronic disease (I); Up-to-Date royalties for section editor on survivorship; Up-to-Date royalties for section editor on survivorship; Up-to-Date royalties for section editor on survivorship; Up-to-Date royalties for section editor on survivorship
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Intrinsic LifeSciences (I); Keryx (I); Keryx (I); Keryx (I); Keryx (I)
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; MolecularMatch; MolecularMatch; MolecularMatch; Navire; Navire; Navire; Navire
Consulting or Advisory Role - Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech; Genentech; Genentech; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Navire; Navire; Navire; Navire; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Redx Pharma; Redx Pharma; Redx Pharma; Redx Pharma; Roche; Roche; Roche; Roche; Symphogen; Symphogen; Symphogen; Symphogen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen; Amgen; Amgen; Amgen
Consulting or Advisory Role - Bayer (I); Bayer (I); Bayer (I); Bayer (I)
 
Charles David Blanke
No Relationships to Disclose
 
Norman Wolmark
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst)
Travel, Accommodations, Expenses - Genentech; Genentech; Genentech; Genentech
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Exelixis; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; Genentech
 
Thomas J. George
Consulting or Advisory Role - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; MedImmune; MedImmune; MedImmune; MedImmune; Novartis; Novartis; Novartis; Novartis; Promega; Promega; Promega; Promega; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MedImmune; MedImmune; MedImmune; MedImmune; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche